Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/ β-catenin signaling pathway in breast cancer

ConclusionsCollectively, this study underscores the potential of combining LOM612 and selinexor as an efficacious anti-BC strategy. The underlying mechanism involves FOXO1's nuclear translocation, which disrupts TCF- β-catenin interactions, thus indirectly inhibiting the Wnt/β-catenin signaling pathway.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research